IL-31: State of the Art for an Inflammation-Oriented Interleukin

被引：37

作者：

Borgia, Francesco ^{[1
]}

Custurone, Paolo ^{[1
]}

Li Pomi, Federica ^{[1
]}

Cordiano, Raffaele ^{[2
]}

Alessandrello, Clara ^{[2
]}

Gangemi, Sebastiano ^{[2
]}

机构：

[1] Univ Messina, Dept Clin & Expt Med, Sect Dermatol, AOUP Gaetano Martino, Via Consolare Valeria 1, I-98125 Messina, Italy

[2] Univ Messina, Sch & Operat Unit Allergy & Clin Immunol, Dept Clin & Expt Med, I-98125 Messina, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 12期

关键词：

IL-31; skin diseases; hematological diseases; cancer; biological drugs; respiratory diseases; allergic diseases; interleukin-31; itch; interleukins; CHRONIC SPONTANEOUS URTICARIA; T-CELL LYMPHOMA; ATOPIC-DERMATITIS; SERUM IL-31; DISEASE SEVERITY; GENE-EXPRESSION; TYPE-2; INFLAMMATION; ENDOMETRIAL CANCER; NC/NGA MICE; PRURITUS;

D O I：

10.3390/ijms23126507

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Interleukin 31 belongs to the IL-6 superfamily, and it is an itch mediator already studied in several diseases, comprising atopic dermatitis, allergic pathologies, and onco-hematological conditions. This research aims to assess the role of this cytokine in the pathogenesis of these conditions and its potential therapeutic role. The research has been conducted on articles, excluding reviews and meta-analysis, both on animals and humans. The results showed that IL-31 plays a crucial role in the pathogenesis of systemic skin manifestations, prognosis, and itch severity. Traditional therapies target this interleukin indirectly, but monoclonal antibodies (Mab) directed against it have shown efficacy and safety profiles comparable with biological drugs that are already available. Future perspectives could include the development of new antibodies against IL-31 both for humans and animals, thus adding a new approach to the therapy, which often has proven to be prolonged and specific for each patient.

引用

页数：20

共 113 条

[1]

Abreu Maria, 2021, Adv Hematol, V2021, P5582581, DOI 10.1155/2021/5582581

[2] Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels [J].